Brigatinib is an ALK inhibitor. It’s used to treat ALK-positive metastatic non-small cell lung cancer. It works by stopping the ALK signaling pathway.
The drug comes in three doses: 30 mg, 90 mg, and 180 mg, all in the form of film-coated tablets. You start with 90 mg a day for the first week, then switch to 180 mg daily to keep it up. The medicine comes in bottles, each with 30 tablets.
